Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 18/20 | 0.62 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540750 | 0.92 | DGAT1 (0.63) | DGAT1ACAT1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL3546664 | 0.90 | DGAT1 (0.60) | DGAT1ACAT1 | |
| SCHEMBL3539571 | 0.87 | DGAT1 (0.69) | DGAT1ACAT1 | |
| SCHEMBL3539695 | 0.87 | DGAT1 (0.61) | DGAT1ACAT1 | |
| SCHEMBL3539496 | 0.86 | DGAT1 (0.66) | DGAT1ACAT1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL3545569 | 0.85 | DGAT1 (0.60) | DGAT1ACAT1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL3540471 | 0.85 | DGAT1 (0.69) | DGAT1ACAT1 | |
| SCHEMBL3541638 | 0.84 | DGAT1 (0.61) | DGAT1ACAT1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL3539463 | 0.83 | DGAT1 (0.60) | DGAT1ACAT1 | |
| SCHEMBL3544471 | 0.83 | DGAT1 (0.76) | DGAT1ACAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | DGAT1 1/4885ACAT1 14/4885SMN1; SMN2 4452/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | DGAT1 1/4885ACAT1 13/4885SMN1; SMN2 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.